BioAtla, Inc. (NASDAQ:BCAB) Position Trimmed by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC trimmed its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB) by 21.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,000 shares of the company’s stock after selling 25,000 shares during the period. Bridgeway Capital Management LLC owned about 0.19% of BioAtla worth $53,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Magnus Financial Group LLC purchased a new stake in shares of BioAtla in the 4th quarter valued at approximately $28,000. Norges Bank purchased a new stake in shares of BioAtla in the 4th quarter valued at approximately $230,000. Highbridge Capital Management LLC purchased a new stake in shares of BioAtla in the 4th quarter valued at approximately $1,484,000. Renaissance Technologies LLC lifted its position in shares of BioAtla by 62.2% in the 4th quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock valued at $490,000 after acquiring an additional 318,196 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after acquiring an additional 100,204 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors.

BioAtla Stock Up 1.7%

BCAB stock opened at $0.44 on Wednesday. BioAtla, Inc. has a 12-month low of $0.24 and a 12-month high of $3.32. The company has a market cap of $25.67 million, a price-to-earnings ratio of -0.26 and a beta of 1.01. The company has a 50 day moving average of $0.37 and a two-hundred day moving average of $0.78.

BioAtla (NASDAQ:BCAB) last released its earnings results on Tuesday, May 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). On average, research analysts anticipate that BioAtla, Inc. will post -1.46 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of BioAtla in a research report on Monday, March 31st.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.